Table 2.
Cancer treatment in the last 30 days and patient outcome.
| Treatment | n of deaths/N of patients (%) SARS-CoV2 RT-PCR∗ |
||
|---|---|---|---|
| All series (N = 302) | Negative (N = 247) | Positive (N = 55) | |
| No. of deaths† | 30 (10%) | 22 (8.9%) | 8 (14.5%) |
| Treatment | |||
| No cancer treatment | 13/108 (12%) | 8/82 (9.7%) | 5/26 (19.2%) |
| Any cancer treatment | 17/194 (8.8%) | 14/165 (8.4%) | 3/29 (10.3%) |
| Cytotoxics | 11/137 (8.0%) | 11/121 (9.1%) | 0/16 (0%) |
| Anti-CD20 | 1/14 (7.1%) | 0/9 (0%) | 1/5 (20%) |
| Anti-PD1/PDL1 | 3/26 (11.5%) | 3/23 (13.0%) | 0/3 (0%) |
| Antiproteasomes | 1/8 (12.5%) | 1/7 (14.2%) | 0/1 (0%) |
| Anti-HER2 | 0/12 (0%) | 0/10 (0%) | 0/2 (0%) |
| Everolimus (mTORi) | 0/4 | 0/4 (0%) | 0 |
| Antiangiogenic TKI | 3/18 (16.6%) | 2/12 (16.6%) | 1/6 (16.6%) |
∗Rates of SARS-COV-2 RT-PCR positivity were not significantly different for any of the treatment categories after correction for the number of tests performed (n = 8, significant p value of p > 0.00625): all p values were above 0.04 using the Chi-square test.). PD1, programmed death protein 1; PD-L1, programmed death ligand 1; TKI, tyrosine kinase inhibitor.
†Death rates were not significantly different for any of the subgroups of treatments after correction for the number of tests performed (n = 8, significant p value of p > 0.00625): all p values were above 0.15 using the Chi-square test.